The FDA decision on Eli Lilly and Co.’s (LLY) Olumiant for an additional indication, i.e., for the treatment of moderate-to-severe atopic dermatitis, is expected in the third quarter.The drug is already approved in the U.S., Europe and more than 70 countries for the treatment of rheumatoid arthritis. Olumiant is also approved in the European Union, Japan and other countries for the treatment of adult patients with moderate to severe atopic dermatitis.For the full year 2020, Olumiant generated worldwide revenue of $638.9 million, up 50 percent from the full year 2019.The most common treatment for mild-to-moderate atopic dermatitis is topical steroids. Oral corticosteroids like Prednisone and Sanofi/Regeneron’s Dupixent are the other treatment options for atopic dermatitis.LLY closed Wednesday’s (Jun.23, 2021) trading at $217.10, down 1.96%.